Valevski A, Klein T, Gazit E, Meged S, Stein D, Elizur A, Narinsky E R, Kutzuk D, Weizman A
Geha Psychiatric Hospital, Rabin Medical Centre, Petah Tiqva, Israel.
Eur J Immunogenet. 1998 Feb;25(1):11-3. doi: 10.1046/j.1365-2370.1998.00091.x.
To further substantiate reports of an association between the major histocompatibility complex subtypes and clozapine-induced agranulocytosis, HLA typing was performed in 61 Jewish Israeli schizophrenic patients, in 11 of whom agranulocytosis developed following clozapine treatment and in 50 (controls) of whom it did not. Of the 11 agranulocytosis patients, seven (63%) were of Ashkenazi origin and four (37%) of Sephardi origin. There was no difference in ethnic origin between the arganulocytosis and non-agranulocytosis groups (chi 2 = 2.4, d.f. = 1, P = 0.11), although the agranulocytosis patients had a higher frequency of the HLA B38 antigen (8/11 or 72% vs. 6/50 or 12%; chi 2 = 18.7, d.f. = 1, P < 0.001). These results suggest that major histocompatibility complex gene products could be involved in clozapine-mediated haematological complications.
为进一步证实主要组织相容性复合体亚型与氯氮平所致粒细胞缺乏症之间存在关联的报道,对61名以色列犹太精神分裂症患者进行了HLA分型,其中11名患者在氯氮平治疗后出现粒细胞缺乏症,50名(对照)患者未出现。在11名粒细胞缺乏症患者中,7名(63%)为阿什肯纳兹人后裔,4名(37%)为西班牙系犹太人后裔。粒细胞缺乏症组和非粒细胞缺乏症组在种族起源上没有差异(卡方检验χ2 = 2.4,自由度d.f. = 1,P = 0.11),尽管粒细胞缺乏症患者中HLA B38抗原的频率更高(8/11或72% 对比 6/50或12%;卡方检验χ2 = 18.7,自由度d.f. = 1,P < 0.001)。这些结果表明,主要组织相容性复合体基因产物可能与氯氮平介导的血液学并发症有关。